Journal
BRITISH JOURNAL OF HAEMATOLOGY
Volume 167, Issue 1, Pages 3-18Publisher
WILEY
DOI: 10.1111/bjh.13000
Keywords
mantle cell lymphoma; immunochemotherapy; novel agents
Categories
Funding
- Celgene
- Pharmacyclic
- Janssen
- Biogen IDEC
- Novartis
- Millennium
Ask authors/readers for more resources
Mantle cell lymphoma is a heterogeneous subtype of non-Hodgkin lymphoma. Conventional treatment with immunochemotherapy followed by autologous stem cell transplantation or intensive immunochemotherapy alone has improved outcomes, but the disease remains incurable. Recent advances in basic and translational research have significantly enhanced our understanding of disease pathogenesis and have sparked the development of novel therapies. Novel agents include the proteasome inhibitor bortezomib, the immunomodulatory agent lenalidomide, the phosphatidylinositol-4,5-bisphosphate 3-kinase pathway inhibitor idelalisib and the Bruton tyrosine kinase inhibitor ibrutinib. Preliminary results from clinical trials, especially from studies of ibrutinib, have proven these agents to be effective. In ongoing studies, these agents are being integrated into conventional immunochemotherapy regimens to hopefully improve patient outcomes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available